We have heard a lot about vaccines for the elderly. But there are also prophylactic drugs being tested that could be tolerated by immune suppressed people who cannot be vaccinated. One of these treatments went into phase 3 trials on Saturday 21st November.
A patient in Manchester was the first in the world join a trial to test whether Astrazeneca’s long-acting antibodies combination will prevent COVID-19 for up to 12 months.
The Phase III trial, which started Saturday 21 November, will recruit 5,000 patients globally to evaluate the safety and effectiveness of the long-acting antibodies.
There will be 9 sites in the UK with 1000 patients.
The NHS Vaccine Research Registry will provide some patients for the study but researchers are urgently calling on more people to volunteer.
Speakers will include:
Sir Mene Pangalos, EVP & Biopharmaceuticals R&D, AstraZeneca
Prof Andrew Ustianowski, Principal Clinical Research Lead, North Manchester General Hospital
Kate Bingham, Chair of the Vaccines Taskforce